News

 

20th November, 2009

Diabetology Limited presents at the European Venture Summit 2009

As one of the most innovative life science companies, Diabetology Limited has been selected to present at the European Venture Summit (EVS), taking place on 30th November and 1st December in Dusseldorf, Germany.

The European Venture Summit, hosted by Europe Unlimited and sponsored by the city of Dusseldorf and the Ministry of Innovation of North Rhine Westphalia showcases the best 120 young companies in Europe, within Life sciences, Cleantech and ICT.  Diabetology Limited qualified through the HiT World Innovation Forum held in Barcelona in June and was rated by expert investors as one of the top 10 investable companies from the contest.

Diabetology Limited will present on 30th November to over 100 specialist European investors at the European Venture Summit – plus corporate partners including Merck, Bayer and GSK, which also bring their focus to emerging technologies and companies.  Expert panels will score each presenting company, celebrating the most investor-ready companies of 2009.

William Stevens, CEO of Europe Unlimited commented “The European Venture Summit is a true celebration of high tech entrepreneurs in Europe.  All presenting companies at the Summit have earned their place through impressing investors across Europe and this brings together a critical mass of the most talented emerging businesses.”

 

Meet me at EVS

 

NOTES TO EDITORS

About Diabetology Limited

Diabetology is a specialty biopharmaceutical company employing a proprietary oral delivery system to administer known bioactives as well as novel compounds for the comprehensive management of diabetes.

Diabetology's lead project is Capsulin, an oral encapsulated formulation of recombinant human insulin for the treatment of patients with type 1 and type 2 diabetes. Diabetology intends to develop Capsulin both as a novel oral anti-diabetic agent for the treatment of patients with type 2 diabetes (Capsulin OAD) and as a replacement to injectable insulin for patients suffering from type 1 and type 2 diabetes (Capsulin IR).

The company’s innovative drug delivery technology, Axcess™ Oral Drug Delivery System, significantly increases the absorption of peptides, proteins and other macromolecules across the intestinal wall when delivered orally without any chemical modification of the active compounds.  It is based on a simple mixture of components consisting entirely of registered pharmacopoeial or GRAS excipients with a long history of pharmaceutical use. The absorption enhancing activities obtained from the formulation of these excipients is entirely novel and forms the basis of five international patent applications.  Diabetology has licensed exclusive rights to Axcess™ for the formulation of oral therapies for diabetes.

About Europe Unlimited

Europe Unlimited delivers investment forums for young, high tech companies across Europe.  Together with its online community of investors and entrepreneurs at www.e-unlimited.com, Europe Unlimited has delivered 2009 investment forums including the Nordic Venture Forum, Benelux Venture Forum and Tech Media Invest.

It also delivers the Eurecan European Venture Forum (EEVC), a year-long contest, sponsored by Caja Navarra, which in 2009 hosted semi-finals in six European countries.  The final, in Barcelona on 14th December, brings together the top25 companies from the semi-finals, with the winner taking a €90,000 prize.

About the European Venture Summit

The European Venture Summit will be hosted in Dusseldorf on 30th November and 1st December.  It is sponsored by the city of Dusseldorf and the Ministry of Innovation of Northrhine Westphalia.

120 young, high tech companies will present at the European Venture Summit to panels of expert investors – they will be scored from 1-10 on factors including business potential, team experience, product technology, competitive position, investment or partnering interest, project quality profile and company presentation quality.

Full information, including presenting companies, expert investors and full programme are available at www.e-unlimited.com/evs.  Media delegates are welcome and can register free of charge online.

ENDS

For more information contact:

Timothy P. Broke-Smith
Corporate Development Officer
Diabetology Limited

Tel: +44 (0)20 7193 8363
Email: t.broke-smith@diabetology.co.uk